Current Neuro-Oncology
Volume
22 Number 3
15 February 2020
Home > Publications > Current Neuro-Oncology > Volume 22, Year 2020 > Number 3, 15 February
Zhao
YY,
Wan QS, Hao Z, Zhu HX, Xing ZL, Li MH.
Clinical
nomogram for predicting the survival of patients with cerebral
anaplastic gliomas.
Medicine
(Baltimore).
2020 Feb 2, 2020;99(10):e19416∟.
doi: 10.1097/MD.0000000000019416∟.
PMID: 32150092∟.
Observational
study.
ˍ
Baehr
A, Trog D, Oertel M, Welsch S, Kröger K, Grauer O, Haverkamp
U, Eich HT.
Re-irradiation
for recurrent glioblastoma multiforme: a critical comparison of
different concepts.
Strahlenther
Onkol.
2020
Feb 3, 2020;196(5):457-464∟.
doi: 10.1007/s00066-020-01585-0∟.
PMID:
32016497∟.
Observational
study.
ˍ
Baxter
PA, Su JM, Onar-Thomas A, Billups CA, Li XN, Poussaint TY, Smith
ER, Thompson PA, Adekunsle A, Ansell P, Giranda VL, Paulino AC,
Kilburn L, Quaddoumi I, Broniscer A, Blaney SM, Dunkel IJ, Fouladi
M.
A
Phase I/II Study of Veliparib (ABT-888) with Radiation and
Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A
Pediatric Brain Tumor Consortium Study.
Neuro
Oncol.
2020
Feb 3, 2020;22(6):875-885∟.
doi: 10.1093/neuonc/noaa016∟.
PMID:
32009149∟.
Interventional
study.
ˍ
Georgescu
MM, Olar A.
Genetic
and histologic spatiotemporal evolution of recurrent, multifocal,
multicentric and metastatic glioblastoma.
Acta
Neuropathol Commun.
2020
Feb 3, 2020;8(1):10∟.
doi: 10.1186/s40478-020-0889-x∟.
PMID:
32014051∟.
Laboratory
investigation.
ˍ
Kushnirsky
M, Feun LG, Gultekin SH, de la Fuente MI.
Prolonged
Complete Response With Combined Dabrafenib and Trametinib After
BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.
JCO
Precis Oncol.
2020 Feb 3, 2020;4:PO.19.00272∟.
doi: 10.1200/PO.19.00272∟.
PMID: 32923904∟.
Case
report.
ˍ
O'Neil
SH, Whitaker AM, Kayser K, Nelson MB, Finlay JL, Dhall G, Sands
S.
Neuropsychological
outcomes on Head Start III: a prospective, multi-institutional
clinical trial for young children diagnosed with malignant brain
tumors.
Neurooncol
Pract. 2020 Feb 3, 2020;7(3):329-337∟.
doi: 10.1093/nop/npz071∟.
PMID: 32537181∟.
Interventional study. ˍ
Pierscianek
D, Ahmadipour Y, Michel A, Chihi M, Oppong MD, Kebir S, Glas M,
Stuschke M, Sure U, Jabbarli R.
Prediction
of Preoperative Survival in Patients With Glioblastoma by Routine
Inflammatory Laboratory Parameters.
Anticancer
Res.
2020
Feb 3, 2020;40(2):1161-1166∟.
doi: 10.21873/anticanres.14058∟.
PMID:
32014969∟.
Observational
study.
ˍ
Tinkle
CL, Campbell K, Han Y, Li Y, Bianski B, Broniscer A, Khan RB,
Merchant TE.
Radiation
dose response of neurologic symptoms during conformal radiotherapy
for diffuse intrinsic pontine glioma.
J
Neurooncol. 2020 Feb 3, 2020;147(1):195-203∟.
doi: 10.1007/s11060-020-03415-w∟.
PMID: 32016716∟.
Observational study.
ˍ
Hata
N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T,
Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao
O, Hiwatashi A, Yoshimoto K, Iihara K.
First-line
bevacizumab contributes to survival improvement in glioblastoma
patients complementary to temozolomide.
J
Neurooncol. 2020 Feb 4, 2020;146(3):451-458∟.
doi: 10.1007/s11060-019-03339-0∟.
PMID: 32020475∟.
Observational
study.
ˍ
Ius
T, Pignotti F, Della Pepa GM, Bagatto D, Isola M, Battistella C,
Gaudino S, Pegolo E, Chiesa S, Arcicasa M, La Rocca G, Olivi A,
Skrap M, Sabatino G.
Glioblastoma:
from volumetric analysis to molecular predictors.
J
Neurosurg Sci. 2020 Feb 4, 2022;66(3):173-186∟.
doi: 10.23736/S0390-5616.20.04850-X∟.
PMID: 32031360∟.
Observational
study˰
ˍ
Kim
CY, Paek SH, Nam DH, Chang JH, Hong YK, Kim JH, Kim OL, Kim SH.
Tumor
treating fields plus temozolomide for newly diagnosed
glioblastoma: a sub-group analysis of Korean patients in the EF-14
phase 3 trial.
J
Neurooncol.
2020
Feb 4. 2020;146(3):399-406∟.
doi: 10.1007/s11060-019-03361-2∟.
PMID:
32020470∟.
Interventional
study.
ˍ
Liu
SJ, Magill ST, Vasudevan HN, Hilz S, Villanueva-Meyer JE, Lastella
S, Daggubati V, Spatz J, Choudhury A, Orr BA, Demaree B, Seo K,
Ferris SP, Abate AR, Oberheim Bush NA, Bollen AW, McDermott MW,
Costello JF, Raleigh DR.
Multiplatform
Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in
Ependymoma.
Cell
Rep.
2020
Feb 4, 2020;30(5):1300-1309.e5∟.
doi: 10.1016/j.celrep.2020.01.018∟.
PMID:
32023450∟.
Laboratory
investigation.
ˍ
Moiyadi
A, Shetty P, Sridhar E, Gota V, Gurjar M, Saicharan G, Singh V,
Srivastava S.
Objective
assessment of intraoperative tumor fluorescence reveals biological
heterogeneity within glioblastomas: a biometric study.
J
Neurooncol.
2020
Feb 4, 2020;146(3):477-488∟.
doi: 10.1007/s11060-019-03338-1∟.
PMID:
32020478∟.
Interventional
study.
ˍ
Yamaki
T, Shibahra I, Matsuda KI, Kanemura Y, Konta T, Kanamori M,
Yamakawa M, Tominaga T, Sonoda Y.
Relationships
between recurrence patterns and subventricular zone involvement or
CD133 expression in glioblastoma.
J
Neurooncol. 2020 Feb 4, 2020;146(3):489-499∟.
doi: 10.1007/s11060-019-03381-y∟.
PMID: 32020479∟.
Observational study. ˍ
Wańkowicz
P,
Rogińska D, Machaliński B, Nowacki P.
Expression
of markers of neural stem and progenitor cells in glioblastoma
multiforme in relation to tumor recurrence and overall
survival.
Arch
Med Sci. 2020 Feb 4, 2020;16(2):481-483∟.
doi: 10.5114/aoms.2020.92857∟.
PMID:
32190162∟.
Laboratory
investigation.
ˍ
Fujita
Y, Kohta M, Sasayama T, et al.
Intraoperative
3-T Magnetic Resonance Spectroscopy for Detection of Proliferative
Remnants of Glioma.
World
Neurosurg.
2020
Feb 5, 2020;137:149–157∟.
doi: 10.1016/j.wneu.2020.01.217∟.
PMID:32035198∟.
Observational
study.
ˍ
Gerstung
M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D,
Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A,
Wintersinger J, Kleinheinz K, Vázquez-García I,
Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N,
Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X,
Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G,
Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz
F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution &
Heterogeneity Working Group, Spellman PT, Wedge DC, Van Loo P;
PCAWG Consortium.
The
evolutionary history of 2,658 cancers.
Nature.
2020
Feb 5, 2020;578(7793):122-128∟.
doi: 10.1038/s41586-019-1907-7∟.
PMID:
32025013∟.
Laboratory investigation.
ˍ
Choi
BD, Gerstner ER, Curry WT Jr.
A
Common Rule for Resection of Glioblastoma in the Molecular
Era.
JAMA
Oncol.
2020 Feb 6, 2020;6(4):503-504∟.
doi: 10.1001/jamaoncol.2019.6384∟.
PMID:
32027348∟.
Comment.
ˍ
Refers
to:
Molinaro
AM, et al., Association of Maximal Extent of Resection of
Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival
Within Molecular Subgroups of Patients With Newly Diagnosed
Glioblastoma.
JAMA
Oncol.
2020
Feb 6, 2020;6(4):495-503∟.
doi: 10.1001/jamaoncol.2019.6143∟.
PMID: 32027343∟.
Observational
study.
ˍ
Garrett
AM, Lastakchi S, McConville C.
The
Personalisation of Glioblastoma Treatment Using Whole Exome
Sequencing: A Pilot Study.
Genes
(Basel).
2020
Feb 6. 2020;11(2):E173∟.
doi: 10.3390/genes11020173∟.
PMID:
32041307∟.
Interventional
study.
ˍ
Molinaro
AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P,
Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A,
Flanigan P, Jahangiri A, Cioffi G, Ostrom Q, Anderson JE, Badve C,
Barnholtz-Sloan J, Sloan AE, Erickson BJ, Decker PA, Kosel ML,
LaChance D, Eckel-Passow J, Jenkins R, Villanueva-Meyer J, Rice T,
Wrensch M, Wiencke JK, Oberheim Bush NA, Taylor J, Butowski N,
Prados M, Clarke J, Chang S, Chang E, Aghi M, Theodosopoulos P,
McDermott M, Berger MS.
Association
of Maximal Extent of Resection of Contrast-Enhanced and
Non-Contrast-Enhanced Tumor With Survival Within Molecular
Subgroups of Patients With Newly Diagnosed Glioblastoma.
JAMA
Oncol. 2020 Feb 6, 2020;6(4):495-503∟.
doi: 10.1001/jamaoncol.2019.6143∟.
PMID: 32027343∟.
Observational study.
ˍ
Roux
A, Pallud J, Saffroy R, Edjlali-Goujon M, Debily MA, Boddaert N,
Sanson M, Puget S, Knafo S, Adam C, Faillot T, Cazals-Hatem D,
Mandonnet E, Polivka M, Dorfmüller G, Dauta A, Desplanques M,
Gareton A, Pages M, Tauziede-Espariat A, Grill J, Bourdeaut F, Doz
F, Dhermain F, Mokhtari K, Chretien F, Figarella-Branger D, Varlet
P.
High-grade
gliomas in adolescents and young adults highlight histomolecular
differences with their adult and paediatric counterparts.
Neuro
Oncol. 2020 Feb 6, 2020;22(8):1190-1202∟.
doi: 10.1093/neuonc/noaa024∟.
PMID:
32025728∟.
Observational
study.
ˍ
Bauer
EK, Stoffels G, Blau T, et al.
Prediction
of survival in patients with IDH-wildtype astrocytic gliomas using
dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine
PET.
Eur
J Nucl Med Mol Imaging.
2020
Feb 7,
2020;47(6):1486-1495∟.
doi: 10.1007/s00259-020-04695-0∟.
PMID:
32034446∟.
Observational
study.
ˍ
Choi
J, Kim SH, Ahn SS, Choi HJ, Yoon HI, Cho JH, Roh TH, Kang SG,
Chang JH, Suh CO.
Extent
of resection and molecular pathologic subtype are potent
prognostic factors of adult WHO grade II glioma.
Sci
Rep.
2020
Feb 7, 2020;10(1):2086∟.
doi: 10.1038/s41598-020-59089-x∟.
PMID:
32034238∟.
Observational study.
ˍ
Finneran
M,
Marotta DA, Altenburger D, Nardone E.
Long-term
Survival in a Patient with Butterfly Glioblastoma: A Case
Report.
Cureus.
2020
Feb 7, 2020;12(2):e6914∟.
doi: 10.7759/cureus.6914∟.
PMID:
32190469∟.
Case
report.
ˍ
Ius
T, Pignotti F, Della Pepa GM, La Rocca G, Somma T, Isola M,
Battistella C, Gaudino S, Polano M, Dal Bo M, Bagatto D, Pegolo E,
Chiesa S, Arcicasa M, Olivi A, Skrap M, Sabatino G.
A
Novel Comprehensive Clinical Stratification Model to Refine
Prognosis of Glioblastoma Patients Undergoing Surgical
Resection.
Cancers
(Basel).
2020 Feb 7, 2020;12(2):E386∟.
doi: 10.3390/cancers12020386∟.
PMID:
32046132∟.
Observational
study.
ˍ
Reardon
DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL,
Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM,
Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD,
Keler T, Davis TA, Sampson JH; ReACT trial
investigators.
Rindopepimut
with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing
Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase
II Trial.
Clin
Cancer Res.
2020
Feb 7, 2020;26(7):1586-1594∟.
doi: 10.1158/1078-0432.CCR-18-1140∟.
PMID:
32034072∟.
Interventional study.
ˍ
Wick
W, Wagener RJ.
Not
Yet Another Negative Trial-ReACTing on Recent Glioblastoma
Trials!
Clin
Cancer Res.
2020
Feb 7, 2020;26(7):1535-1537∟.
doi: 10.1158/1078-0432.CCR-19-4032∟.
PMID:
32034079∟.
Comment.
ˍ
Refers
to:
Reardon
DA, et al., Rindopepimut
with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing
Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase
II Trial.
Clin
Cancer Res. 2020 Feb 7, 2020;26(7):1586-1594∟.
doi: 10.1158/1078-0432.CCR-18-1140∟.
PMID: 32034072∟.
Interventional study.
ˍ
Zhao
Z, Zhang C, Li M, Shen Y, Feng S, Liu J, Li F, Hou L, Chen Z,
Jiang J, Ma X, Chen L, Yu X.
Applications
of cerebrospinal fluid circulating tumor DNA in the diagnosis of
gliomas.
Jpn
J Clin Oncol. 2020 Feb 10, 2020;50(3):325-332∟.
doi:10.1093/jjco/hyz156∟.
PMID:
32039443∟.
Observational
study.
ˍ
Acharya
S, Liu JF, Tatevossian RG, Chiang J, Qaddoumi I, Gajjar A, Walker
D, Harreld J, Merchant TE, Ellison DW.
Risk
stratification in pediatric low-grade glioma and glioneuronal
tumor treated with radiation therapy: An integrated
clinicopathologic and molecular analysis.
Neuro
Oncol.
2020
Feb 13, 2020;22(8):1203-1213∟.
doi:10.1093/neuonc/noaa031∟.
PMID:
32052049∟.
Observational
study.
ˍ
Werlenius
K, Fekete B, Blomstrand M, Carén H, Jakola AS, Rydenhag B,
Smits A.
Patterns
of care and clinical outcome in assumed glioblastoma without
tissue diagnosis: A population-based study of 131 consecutive
patients.
PLoS
One. 2020 Feb 13, 2020;15(2):e0228480∟.
doi: 10.1371/journal.pone.0228480∟.
PMID:
32053655∟.
Observational
study.
ˍ
Dutoit
V,
Philippin G, Widmer V, Marinari E, Vuilleumier A, Migliorini D,
Schaller K, Dietrich PY.
Impact
of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma
Patients.
Front
Oncol. 2020 Feb 14, 2020;10:89∟.
doi: 10.3389/fonc.2020.00089∟.
PMID:
32117743∟.
Observational study.
ˍ
Goerig
NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA,
Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz
F, Semrau S, Gaipl US, Fietkau R.
Early
mortality of brain cancer patients and its connection to
cytomegalovirus reactivation during radiochemotherapy.
Clin
Cancer Res.
2020
Feb 14, 2020;26(13):3259-3270∟.
doi: 10.1158/1078-0432.CCR-19-3195∟.
PMID:
32060103∟.
Observational
study.
ˍ